Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) had its price target raised by equities researchers at Jefferies Financial Group from $54.00 to $58.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Jefferies Financial Group's target price would indicate a potential upside of 24.81% from the company's previous close.
Other equities analysts also recently issued reports about the stock. The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th. HC Wainwright restated a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Guggenheim reaffirmed a "buy" rating and set a $78.00 price objective (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Barclays reduced their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $63.67.
View Our Latest Stock Report on TARS
Tarsus Pharmaceuticals Stock Up 6.7 %
Shares of NASDAQ TARS traded up $2.90 during midday trading on Thursday, reaching $46.47. The company's stock had a trading volume of 625,250 shares, compared to its average volume of 641,239. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -12.20 and a beta of 1.05. The stock has a 50 day simple moving average of $50.14 and a 200-day simple moving average of $43.61.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Equities research analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
Institutional investors have recently modified their holdings of the business. Crowley Wealth Management Inc. bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $25,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $44,000. R Squared Ltd bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $53,000. Quarry LP bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $166,000. Finally, HighTower Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $207,000. Institutional investors own 90.01% of the company's stock.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
See Also
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
